Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based CFO’ operating in the Clinical Trials space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Brian Jung
CFO of AiCure
Brian Jung is the CFO of AiCure.
Follow Brian Jung:
About AiCure: AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments.
Bryan Happ
Chief Financial Officer of AOD Software
As CFO, Bryan Happ oversees all financial planning and analysis for AOD Software. In his role Bryan helps pursue strategic growth and manages all aspects of finance, capital and human resources to ensure AOD maintains a solid financial foundation and achieves sustained growth. Bryan launched his career at Ernst & Young and has more than 20 years of private and public accounting and finance experience. Bryan holds a B.A. in Economics from Cornell University and a Masters of Accounting from Northeastern University, and is a Certified Public Accountant
Follow Bryan Happ:
About AOD Software: A Fort Lauderdale, Fla.-based portfolio company of Primus Capital.
Brian Hochheimer
Chief Financial Officer of Emmes
Brian Hochheimer is the CFO of The Emmes Corporation.
Follow Brian Hochheimer:
About Emmes: Emmes is a clinical research collaborator.
Ivan Ivankovich
CFO of Sanguine
Co-Founder of Full Stack Finance.
Follow Ivan Ivankovich:
About Full Stack Finance, LLC, Markaaz, Sanguine: Sanguine develops innovative technology solutions for clinical researchers.
Chris Lafond
Chief Financial Officer of Intralinks
Chris Lafond is the CFO at Intralinks.
Follow Chris Lafond:
About Intralinks: Intralinks is a technology company that offers a range of firewall collaboration solutions.
Asad Sajwani
CFO of VirTrial
Asad Sajwani is the Chief Financial Officer at VirTrial.
Follow Asad Sajwani:
About VirTrial: Virtrial is a technology company using a stable, long-standing telehealth platform to transform the clinical trial industry.
Thomas E Marren
Chief Financial Officer of WIRB-Copernicus Group
Follow Thomas E Marren:
About WIRB-Copernicus Group: WCG accelerates the development of new medical therapies by improving the conduct and quality of clinical trials.
Thomas R. Staab
SVP & CFO of BioCryst Pharmaceuticals
Tom Staab joined the BioCryst Leadership Team in July 2011, bringing his skill and experience regarding the financial stewardship of publically-traded companies, development and commercialization of pharmaceutical products and raising capital through strategic partnerships, equity and debt financings. Mr. Staab most recently served as Executive Vice President, CFO and Treasurer of Inspire Pharmaceuticals from May 2003 through its $430 million acquisition by Merck & Co., Inc. in May 2011. Prior to joining Inspire, he held the senior financial positions of Acting CFO and Treasurer at Triangle Pharmaceuticals, Inc. through its $480 million acquisition by Gilead Sciences, Inc. Additionally, Mr. Staab spent eight years working for PricewaterhouseCoopers LLP providing audit and business advisory services to national and multi-national corporations in the biotechnology, pharmaceutical, pulp and paper and communications industries. Tom currently serves on the Board of the NC Biosciences Organization (NCBIO) and is a member of its Audit Committee, and he has received several awards for his contribution and leadership to other organizations. He is a Certified Public Accountant and received a B.S. in Business Administration and a Masters of Accounting from the University of North Carolina at Chapel Hill.
Follow Thomas R. Staab:
About BioCryst Pharmaceuticals: BioCryst has over 80 employees spread across their two locations in Birmingham, Alabama and Durham, North Carolina.
Maria Kraus
Chief Financial Officer of AES
Follow Maria Kraus:
About AES: AES provides clinical trial acceleration solutions for various medical sectors.
John C. Oakley
CFO of KNOW Bio
John C. Oakley is the CFO at KNOW Bio.
Follow John C. Oakley:
About KNOW Bio, Vast Therapeutics: KNOW Bio, LLC develops and produces nitric oxide-based therapies.
John C. Oakley
CFO of KNOW Bio
John C. Oakley is the CFO at KNOW Bio.
Follow John C. Oakley:
About KNOW Bio, Vast Therapeutics: KNOW Bio, LLC develops and produces nitric oxide-based therapies.
Mark W. Hahn
Executive Vice President & Chief Financial Officer of Cempra
Mr. Hahn has over 25 years of experience as a senior financial executive in biotechnology and high technology companies. he has conducted over $500 million in financial transactions for both public and private companies. Prior to joining Cempra, Mark was CFO of Athenix Corp., a leading agricultural biotechnology company where he led the company in its $400 million merger with Bayer CropScience. He previously was the CFO of several rapidly growing technology companies including BuildLinks, Inc. and Charles & Colvard, Ltd., where he led the growth of the firm from three to 75 employees and spearheaded that company’s IPO. Mark began his career with Ernst & Young. Mr. Hahn holds a Bachelor of Business Administration degree in Accouning and Finance from the University of Wisconsin-Milwaukee and is a Certified Public Accountant in the State of Maryland.
Follow Mark W. Hahn:
About Cempra, Verona Pharma: Cempra develops medicines for the treatment of bacterial infections and chronic illnesses.
Mike Johnson
CFO of Cord Blood Registry
Mike Johnson joined CBR as CFO in January 2013. Mike was most recently the CFO of Fenwal, a global blood technology company dedicated to supporting transfusion medicine and cell therapies. He successfully managed a carve-out of the Fenwal business from Baxter in 2006. From 2006 to 2012 he led the global finance and IT organizations through a business transformation that supported international integration of a stand-alone business and resulted in significant value creation. TPG, a large private equity firm, recently sold the business to Fresenius. Prior to Fenwal, he spent almost 10 years in senior financial roles at Dade Behring, a leading medical diagnostics company, including Corporate Controller, and V.P. Finance for the manufacturing, supply chain and R&D organizations. Mike has a B.S. in Accounting from the University of Illinois and an M.B.A. from the University of Chicago.
Follow Mike Johnson:
About Cord Blood Registry: Cord Blood Registry is the world’s largest newborn stem cell company.
Ken Mace
Chief Financial Officer of Alzheon
Follow Ken Mace:
About Alzheon: Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative.
Richard Aguinaldo
Chief Financial Officer of TrialScope
Follow Richard Aguinaldo:
About TrialScope: TrialScope, which offers clinical-trial-disclosure and transparency-management technologies.
Dan Shore
Chief Financial Officer of Broad Institute
Dan Shore is the chief financial officer of the Broad Institute of MIT and Harvard. He focuses on financial strategy and operations with the aim of propelling great science. Previously, Shore served as the integration lead at Brandwatch, a consumer insight analytics company, guiding their merger with Crimson Hexagon. Prior to the merger, Shore led Crimson Hexagon’s finance team as SVP and CFO. Shore also served as CFO at Onshape, a CAD software company. Before his time in the tech sector, Shore was CFO at Harvard University from 2008 to 2014, where he shepherded the university through the global financial crisis. Before the CFO appointment, he served as Harvard’s director of the Office of Budgets and Financial Planning. There, he established the university’s multi-year financial planning process and helped launch the Harvard Corporation committee on finance. He fostered new approaches to a range of financial challenges, including managing liquidity and debt, funding major initiatives and capital projects, and procuring goods and services. Previously, Shore was a consultant at McKinsey & Company and a corporate attorney at Nutter McClennen & Fish. Shore earned his B.A. from Duke University, his J.D. from the University of Pennsylvania, and his M.B.A. from the University of Virginia.
Follow Dan Shore:
About Broad Institute: The Broad Institute brings together a diverse group of individuals from across its partner institutions to confront biomedical challenges.
Molly Henderson
Chief Financial Officer of UroGen Pharma
Molly Henderson is the Chief Financial Officer at UroGen Pharma.
Follow Molly Henderson:
About UroGen Pharma: UroGen Pharma is a clinical-stage biopharmaceutical company.
Gerard Fleury
Chief Financial Officer of Paragon Bioservices
Gerard Fleury joined Pii as Chief Financial Officer in 2016. Gerard has over 25 years of experience as a CFO, COO or CEO of companies in the life science, healthcare, healthcare IT and software sectors. Prior to joining Pii, Gerard spent the early part of his career working for Deloitte & Touche, rising to senior manager in their Emerging Business and Corporate Finance Groups. During his career, Gerard has managed companies through turn-around situations, as well as through growth and optimization cycles. In addition, he has served on the boards of directors or advisors of software, the internet, data center, and utility companies. Gerard also has experience in establishing and/or managing both domestic and international subsidiaries, including companies in China, Germany, Hong Kong, Singapore, the Netherlands, and the UK. Gerard has completed numerous financing transactions, including venture capital, private equity, leasing, and commercial banking, and has experience in mergers and acquisitions, both on the buy-side and sell-side. In 1980, Gerard earned a bachelor’s degree in business administration with a concentration in accounting from Towson University. He also successfully completed the CPA Exam in 1980.
Follow Gerard Fleury:
About Paragon Bioservices, Pharmaceutics International: Founded in 1990, Paragon Bioservices is a CDMO whose focus is complex biopharmaceuticals (AAV, oncolytic virus, next-generation vaccines).
Gene Wahnefried
CFO & COO of Advanced Tear Diagnostics (ATD)
Follow Gene Wahnefried:
About Advanced Tear Diagnostics (ATD): Develops and markets a highly specialized point-of-care (POC) lab testing system.
Jason Robertson
CFO of Star Dental Partners
Jason Robertson currently works as Chief Financial Officer at Star Dental Partners.
Follow Jason Robertson:
About Star Dental Partners: Star Dental Partners is a dental support organization that partners with dentists to provide customized solutions.
Jason Robertson
CFO of Star Dental Partners
Jason Robertson currently works as Chief Financial Officer at Star Dental Partners.
Follow Jason Robertson:
About Star Dental Partners: Star Dental Partners is a dental support organization that partners with dentists to provide customized solutions.
Jack Weinstein
Chief Financial Officer & Treasurer of Relief Therapeutics
Follow Jack Weinstein:
About Relief Therapeutics: Relief Therapeutics is a clinical stage biotechnology company.
Roger Jensen
Chief Financial Officer of DxNA
President of Centennial Capital Corporation, a financial advisory firm specializing in Mergers and Acquisitions, Corporate Finance and Reorganization, and Strategic Growth Planning. He has over 25 years senior management experience in a variety of industries including Life Science and has been engaged with DxNA since 2012. From 1997-2001 he served as Executive Vice President for Apogent Technologies where he had the lead role in creating and managing Apogent’s $200 million Microbiology Group. In this and other corporate capacities he has developed and successfully introduced numerous diagnostic products into both the clinical and research markets. He has earned an MBA and CPA having started his career with KPMG (formerly Peat, Marwick) in their business advisory practice. He brings to DxNA significant business, management and financial expertise.
Follow Roger Jensen:
About DxNA: DxNA develops integrated systems and tests for rapid real-time PCR molecular diagnostics.
James Maples
Chief Financial Officer & Director of Administration of DxNA
Mr. James Maples has operated as Chief Financial Officer for DxNA LLC and other preceding related companies. He has lectured at Dixie State Collage on Entrepreneurship and at Utah State University has taught upper division Marketing. Mr. Maples has had a wide and varied career in commercial real estate as a broker and commercial real-estate development. He has been an owner and manager of several small businesses and has served as General Manager of a technical plastics manufacturing company and a Hologram manufacturing company. He received his B,S, in Production Management and his M.B.A. from Utah State University.
Follow James Maples:
About DxNA: DxNA develops integrated systems and tests for rapid real-time PCR molecular diagnostics.
